Monday, December 2, 2013
Businesses are being invited to develop standard tools and services that will help grow the emerging industry of synthetic biology. Up to $5.1 million is being made available by the Technology Strategy Board, together with the Biotechnology and Biological Sciences Research Council (BBSRC), the Engineering and Physical Sciences Research Council (EPSRC) and the Welsh Government.
HeartWare International, an innovator of less invasive, miniaturized circulatory support technologies for the treatment of advanced heart failure, has acquired CircuLite, developer of the SYNERGY Circulatory Support System, designed to treat less sick, ambulatory, chronic heart failure patients who are not yet inotrope-dependent.
Southern California-based CRO WCCT Global has implemented an international patient recruitment strategy, led by the use of an in-depth social media strategy and optimized search engine approach. WCCT Global has a complete design team able to produce any print materials needed for a campaign in any language. Each print material for a study is connected to a digital website where the viewer can scan with his or her smart phone and sign up for a study without having to make a phone call.
Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has a new strategic insights report that found in response to widespread medication nonadherence, pharmaceutical companies should factor medication adherence interventions into their drug development process.
FDA warning letters drop as audit preparation increases
SillaJen, a privately-held biotherapeutics and contract research company focused on the development of targeted biological products for cancer, will acquire San Francisco-based Jennerex, a privately-held, clinical-stage biotechnology company developing best-in-class targeted oncolytic immunotherapies for solid tumors.
A group of hospitals and research institutions across Cincinnati and Northern Kentucky has formed a collaborative Institutional Review Board (IRB) agreement that will allow any of the six participating sites to serve as the IRB of record for research conducted across multiple participating study sites.
Genomic Health, a provider of genomic-based diagnostic tests, will exclusively license Almac Group’s technology and intellectual property to further develop, validate and subsequently commercialize a multi-gene test to predict benefit from DNA damage-based chemotherapy drugs, such as the commonly used anthracycline-based regimens, in breast cancer. Such a test would be particularly useful for high-risk breast cancer patients who are eligible for chemotherapy based on their Oncotype DX score.